Correction to: Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.
作者信息
Grinda Thomas, Rassy Elie, Pistilli Barbara
机构信息
Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.
出版信息
Curr Treat Options Oncol. 2023 May;24(5):466-467. doi: 10.1007/s11864-023-01092-1.
Abstract
摘要
相似文献
1
Correction to: Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.对《乳腺癌中的抗体药物偶联物革命：前行之路》的更正
Curr Treat Options Oncol. 2023 May;24(5):466-467. doi: 10.1007/s11864-023-01092-1.
2
My Road Ahead study protocol: a randomised controlled trial of an online psychological intervention for men following treatment for localised prostate cancer.我的前路研究方案：一项针对局部前列腺癌治疗后男性的在线心理干预的随机对照试验。
BMC Cancer. 2014 Feb 11;14:83. doi: 10.1186/1471-2407-14-83.
3
A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.一种新型人源化 MUC1 抗体药物偶联物，用于治疗曲妥珠单抗耐药的乳腺癌。
Acta Biochim Biophys Sin (Shanghai). 2021 Dec 8;53(12):1625-1639. doi: 10.1093/abbs/gmab141.
4
Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.用于治疗脑转移 HER2+乳腺癌肿瘤的抗癌抗体曲妥珠单抗-黑素转铁蛋白偶联物（BT2111）：一项体内研究。
Pharm Res. 2016 Dec;33(12):2930-2942. doi: 10.1007/s11095-016-2015-0. Epub 2016 Aug 15.
5
Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.
Mol Cancer Ther. 2019 Nov;18(11):2182. doi: 10.1158/1535-7163.MCT-19-0749.
6
Expression profiling in pancreatic cancer research: the initial steps and the road ahead.胰腺癌研究中的表达谱分析：初始步骤与未来之路。
Curr Opin Gastroenterol. 2003 Sep;19(5):467-72. doi: 10.1097/00001574-200309000-00005.
7
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.Sacituzumab govitecan：一种新型抗体药物偶联物的过去、现在和未来及未来展望。
Future Oncol. 2022 Sep;18(28):3199-3215. doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7.
8
An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.一种整合的多分析物药代动力学模型，用于描述曲妥珠单抗-美坦新偶联物（T-DM1）的清除途径，并评估人表皮生长因子受体 2 阳性转移性乳腺癌患者减少药代动力学采样的情况。
Clin Pharmacokinet. 2013 Aug;52(8):657-72. doi: 10.1007/s40262-013-0060-y.
9
The EV revolution: The road ahead for critical raw materials demand.电动汽车革命：关键原材料需求的未来之路。
Appl Energy. 2020 Dec 15;280:115072. doi: 10.1016/j.apenergy.2020.115072. Epub 2020 Oct 9.
10
Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells.新型抗叶酸受体1（FOLR1）抗体药物偶联物MORAb-202在乳腺癌和非小细胞肺癌细胞中的研究
Antibodies (Basel). 2021 Feb 1;10(1):6. doi: 10.3390/antib10010006.
引用本文的文献
1
Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody-Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs.乳腺癌的靶向治疗：抗体药物偶联物（一种化学 - 生物杂交药物）的优势与进展
Cancers (Basel). 2024 Oct 17;16(20):3517. doi: 10.3390/cancers16203517.
2
Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).与三阴性乳腺癌（TNBC）相关的分子途径和治疗靶点。
Mol Cell Biochem. 2024 Apr;479(4):895-913. doi: 10.1007/s11010-023-04772-6. Epub 2023 May 29.
Zotero 插件